Q2 2024 Earnings Call Transcript November 12, 2024 Operator: Good day and thank you for standing by. Welcome to the Roivant ...

AI has shown promise by analysing data from patient records to recognise complex patterns within large datasets, which can aid in the ...

Company expects to commence Phase 3 trial of Descartes-08 in patients with myasthenia gravis in 1H2025 following recent meeting with U.S. Food ...

Q3 2024 Earnings Call Transcript October 31, 2024 Operator: Good morning. My name is Rob and I will be your conference ...

Priovant Therapeutics was formed in 2021 through a partnership between Roivant Sciences and Pfizer (NYSE: PFE) with a focus on developing new treatments for rare autoimmune diseases with high ...

Bank of America Securities analyst Tazeen Ahmad has reiterated their bullish stance on ARGX stock, giving a Buy rating today. Tazeen ...

Initiation of patient enrollment expected by year-end 2024 in Ntrust-2, a clinical trial of NKX019 for the treatment of systemic sclerosis, myositis and vasculitis. As previously announced, the ...

The findings, published in Immunity, could lead to new treatments targeting IL-1β ... or patients with the autoimmune disease juvenile dermatomyositis. Mitochondria are normally degraded during ...

To evaluate the influence of environmental factors and prematurity relating to juvenile dermatomyositis (JDM), its course and refractoriness to treatment ... course remained together in the same group ...

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless ...

Additionally, the pipeline includes new treatments for conditions like Cushing ... and a product targeting dermatological myositis, a condition that has historically lacked targeted therapies.

We really only had one additional subject in each dose arm of the treatment failure, and we had sustained improvement from baseline on important metrics like retinal vascular leakage, CST and macular ...